NH HB1292

Expands New Hampshire's Right to Try Act beyond terminal illness to include "qualifying severe illness," defined as chronic and debilitating conditions, allowing patients with such conditions to access drugs, biologics, or devices not yet approved by the FDA

Removes the requirement that drugs, biologics, or devices must have completed phase one clinical trials, broadening access to unapproved treatments when a physician determines no comparable FDA-approved options are available

Establishes regulatory framework for regenerative stem cell therapies, permitting physicians to perform non-FDA-approved stem cell treatments for orthopedics, wound care, or pain management when stem cells are sourced from FDA-registered and accredited facilities

Requires physicians offering stem cell therapy to provide specific advertising disclosures and obtain signed informed consent detailing the treatment's unapproved status, anticipated results, and potential risks

Prohibits use of stem cells derived from a fetus or embryo after an abortion, making willful violation a class B felony; effective date is January 1, 2027